Targeted Medicines Delivery
To unlock the full-potential of advanced therapeutics, the development of smart delivery systems, capable of complex responses in the body, is critical.
Antibody Drug Conjugates (ADCs) have been developed as ‘magic bullets’ in cancer chemotherapy, combining the specificity of monoclonal antibodies with the potency of chemotherapeutic drugs, connected by a chemical linker. ADCs allow cell-killing agents to be delivered directly to the target site, avoiding healthy tissue.
Unique PEGabet Technology
Exactmer’s PEGabet Technology offers a bespoke range of next-generation linkers for ADCs and drug delivery systems.
PEGabets join together Exactmer’s bespoke ethylene-glycol monomers, each with a functional side-group, to generate polymers that combine the gold-standard ‘stealth’ properties of polyethylene glycol, with multiple, diverse functionalities, and high drug-loadings.
Unlocking Innovation
Current ADC-linkers are typically only capable of carrying a single payload per linker. This means multiple linker-payloads are required to achieve high Drug-to-Antibody Ratios (DARs), but if the antibody becomes too ‘decorated’ in this way it can lose affinity for the target site, aggregate in formulation, and hinder its stealth properties. Low DARs (usually just 2-4 drugs per antibody) prevail, increasing complexity and cost of the medicine.
Linkers capable of conjugating multiple payloads, with capacity to conjugate additional cargo such as cell-penetrating agents, or combination therapeutics, whist retaining stealth-like properties, have the capacity to revolutionise ADCs.
PEGabets offer cutting-edge drug delivery scaffolds, resulting in unparalleled, bespoke functionality, and enhanced control over formulations. Useful beyond the field of chemotherapeutic delivery, PEGabets could be used to transport other difficult-to-deliver therapeutics in the body, including oligos.
The journey starts here
We are committed to support the delivery of first-class advanced pharmaceuticals. Let’s explore how we can work together.
Follow us
